Literature DB >> 11267943

Efficient gene transduction by RGD-fiber modified recombinant adenovirus into dendritic cells.

R Asada-Mikami1, Y Heike, S Kanai, M Azuma, K Shirakawa, Y Takaue, V Krasnykh, D T Curiel, M Terada, T Abe, H Wakasugi.   

Abstract

Dendritic cells (DC) are important antigen-presenting cells in the development of an anti-tumor T cell response. To extend the range of current immuno / gene therapies, we tested luciferase-expressing RGD-adenovirus (Ad) (Ad5lucRGD)-mediated transduction into DC. Phenotypically characterized DC were generated from peripheral blood CD14(+) cells by incubation with granulocyte-macrophage colony-stimulating factor, interleukin-4 and tumor necrosis factor alpha. On the 7th day of culture, the cells became mature DC with a CD1a(+), CD11c(+), CD80(+), CD83(+), CD86(+), human leukocyte antigen (HLA)-DR(+), CD14- phenotype. The expression of alpha( v)beta(3) integrin was enhanced on day 3 and returned to the basal level on day 7. We then compared the transduction efficiency of an Ad5lucRGD system to that using conventional Ad, in cells harvested on days 1, 3 and 7 of culture. Luciferase activity was negligible in AdCMVLuc, but remarkable in cells processed with Ad5lucRGD. Activity was maximal in cells that had been cultured for 3 days. Recombinant Ad5 fiber knob protein blocked AdCMVLuc- and Ad5lucRGD-mediated gene transduction by 90% and 20%, respectively. Surface markers and cytokine production were not affected by Ad5lucRGD-mediated transduction.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11267943      PMCID: PMC5926705          DOI: 10.1111/j.1349-7006.2001.tb01098.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  33 in total

1.  High gradient magnetic cell separation with MACS.

Authors:  S Miltenyi; W Müller; W Weichel; A Radbruch
Journal:  Cytometry       Date:  1990

Review 2.  Ex-vivo gene therapy using cytokine-transduced tumor vaccines: molecular and clinical pharmacology.

Authors:  J W Simons; B Mikhak
Journal:  Semin Oncol       Date:  1998-12       Impact factor: 4.929

3.  CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells.

Authors:  L J Zhou; T F Tedder
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-19       Impact factor: 11.205

4.  Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins.

Authors:  T J Wickham; E Tzeng; L L Shears; P W Roelvink; Y Li; G M Lee; D E Brough; A Lizonova; I Kovesdi
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

5.  Retroviral interleukin-7 gene transfer into human dendritic cells enhances T cell activation.

Authors:  J Westermann; A Aicher; Z Qin; Z Cayeux; K Daemen; T Blankenstein; B Dörken; A Pezzutto
Journal:  Gene Ther       Date:  1998-02       Impact factor: 5.250

6.  Molecular and functional characteristics of dendritic cells generated from highly purified CD14+ peripheral blood monocytes.

Authors:  W F Pickl; O Majdic; P Kohl; J Stöckl; E Riedl; C Scheinecker; C Bello-Fernandez; W Knapp
Journal:  J Immunol       Date:  1996-11-01       Impact factor: 5.422

7.  HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses.

Authors:  R P Tomko; R Xu; L Philipson
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-01       Impact factor: 11.205

Review 8.  Targeted adenoviral vectors for cancer gene therapy.

Authors:  G Bilbao; J Gómez-Navarro; D T Curiel
Journal:  Adv Exp Med Biol       Date:  1998       Impact factor: 2.622

9.  Generation of bcr-abl specific cytotoxic T-lymphocytes by using dendritic cells pulsed with bcr-abl (b3a2) peptide: its applicability for donor leukocyte transfusions in marrow grafted CML patients.

Authors:  Y Osman; M Takahashi; Z Zheng; T Koike; K Toba; A Liu; T Furukawa; S Aoki; Y Aizawa
Journal:  Leukemia       Date:  1999-02       Impact factor: 11.528

Review 10.  Dendritic cells as adjuvants for immune-mediated resistance to tumors.

Authors:  G Schuler; R M Steinman
Journal:  J Exp Med       Date:  1997-10-20       Impact factor: 14.307

View more
  3 in total

1.  Targeting of adenovirus via genetic modification of the viral capsid combined with a protein bridge.

Authors:  Nikolay Korokhov; Galina Mikheeva; Alexander Krendelshchikov; Natalya Belousova; Vera Simonenko; Valentina Krendelshchikova; Alexander Pereboev; Alexander Kotov; Olga Kotova; Pierre L Triozzi; Wayne A Aldrich; Joanne T Douglas; Kin-Ming Lo; Papia T Banerjee; Stephen D Gillies; David T Curiel; Victor Krasnykh
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

2.  HIV-1 tat promotes integrin-mediated HIV transmission to dendritic cells by binding Env spikes and competes neutralization by anti-HIV antibodies.

Authors:  Paolo Monini; Aurelio Cafaro; Indresh K Srivastava; Sonia Moretti; Victoria A Sharma; Claudia Andreini; Chiara Chiozzini; Flavia Ferrantelli; Maria R Pavone Cossut; Antonella Tripiciano; Filomena Nappi; Olimpia Longo; Stefania Bellino; Orietta Picconi; Emanuele Fanales-Belasio; Alessandra Borsetti; Elena Toschi; Ilaria Schiavoni; Ilaria Bacigalupo; Elaine Kan; Leonardo Sernicola; Maria T Maggiorella; Katy Montin; Marco Porcu; Patrizia Leone; Pasqualina Leone; Barbara Collacchi; Clelia Palladino; Barbara Ridolfi; Mario Falchi; Iole Macchia; Jeffrey B Ulmer; Stefano Buttò; Cecilia Sgadari; Mauro Magnani; Maurizio P M Federico; Fausto Titti; Lucia Banci; Franco Dallocchio; Rino Rappuoli; Fabrizio Ensoli; Susan W Barnett; Enrico Garaci; Barbara Ensoli
Journal:  PLoS One       Date:  2012-11-13       Impact factor: 3.240

3.  In vivo gene delivery and expression by bacteriophage lambda vectors.

Authors:  H A Lankes; C N Zanghi; K Santos; C Capella; C M P Duke; S Dewhurst
Journal:  J Appl Microbiol       Date:  2007-05       Impact factor: 3.772

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.